The relationship between chronic obstructive pulmonary disease (COPD) and chronic bronchitis ... including diagnostic criteria and management of acute exacerbation of CB (AECB) in the elderly ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

Azithromycin taken daily at a dose of 250 mg was reported to significantly reduce the rate of COPD exacerbations in severe COPD patients over a period of 1 year. QoL measures and exacerbation ...

So a COPD exacerbation is a period where people with COPD will notice an acute deterioration in their symptoms. And these will probably last a few days, and they may experience shortness of breath ...

Azithromycin (as dihydrate) 100mg/5mL, 200mg/5mL; pwd for oral susp. Use packets only for doses equal to 1g. COPD: 500mg once daily for 3 days; or 500mg once for 1 day, then 250mg once daily for 4 ...

Azithromycin (as dihydrate) 1g/packet (single-dose); pwd for oral susp. Use packets only for doses equal to 1g. COPD: 500mg once daily for 3 days; or 500mg once for 1 day, then 250mg once daily ...

SGLT-2 inhibitors and GLP-1 receptor agonists are linked to a reduced risk of COPD exacerbations in patients with type 2 ...

Both SGLT2 inhibitors and GLP-1s lowered moderate or severe COPD exacerbation risk vs. DPP-4 inhibitors. Weight loss and SGLT2 inhibitors’ glucosuria effect may explain the findings. Sodium ...